From day one, our goal has been to leverage our unique proprietary technologies and know-how to build a company that would bring safer, more cost-effective and more convenient therapeutic products to under served patient populations in both existing and emerging markets. Below you will find the latest updates for our leading indications including clinical trial results, FDA & EMA designations.
Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA congress
Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th fibrosis at the 56th ERA/EDTA congress
Prometic presents new PBI-4050 and Ryplazim (plasminogen) data on lung fibrosis at the 2019 ATS conference
Prometic today announced the presentation of three scientific posters on the Company’s lead small molecule and plasma-derived drug product candidates, respectively PBI-4050 and Ryplazim™.
Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome
The protocol for the Phase 3 clinical trial will be designed to meet expectations from both the U.S and EU regulatory agencies.
Prometic announces second annual plasminogen deficiency awareness week
This initiative, sponsored by Prometic, aims to raise awareness and improve understanding of this rare disease and its effects. Plasminogen Deficiency Awareness Week is a free 4-day online event
Find out more about PBI-4050Learn More
Prometic announces positive feedback from FDA type-c meeting on Ryplazim (plasminogen) BLA
Implementation plan for additional analytical assays and in-process controls confirmed and PLI finalizing process performance qualification (PPQ) protocol in order to proceed with the manufacturing
Prometic’s Plasminogen (Ryplazim™) granted orphan drug designation for the treatment of Idiopathic Pulmonary Fibrosis (IPF)
In a gold-standard animal model proven to emulate pulmonary fibrosis in humans, Prometic’s Plasminogen (Ryplazim™) performed favorably compared to recently- approved IPF drugs to treat this condition.